WO2014134830A1 - Edible composition, food product comprising same, and preparation method for the food product - Google Patents

Abstract

Provided are an edible composition, a food product comprising same, and a preparation method for the food product. The edible composition comprises: 120 parts by weight of sacha inchi, 10-90 parts by weight of Astragalus, 10-80 parts by weight of poria, 30-100 parts by weight of inulin, 30-90 parts by weight of corn pollen, 10-90 parts by weight of Strophanthus divaricatus, and 20-120 parts by weight of a functional sugar.

Description

 Edible composition and food containing same, preparation method of the same

Technical field

 The invention belongs to the field of health foods, and in particular relates to an edible composition and a food containing the edible composition

Π

Hey.

Background technique

 The immune system in the human body is composed of immune organs and immune cells. It is our natural natural barrier. It not only protects against foreign bacteria and other harmful substances, but also eliminates cells that are aging, mutated, deteriorated or dead in the body. Keep your body healthy. Immunity is the ability of the human body to resist the invasion of external evils and maintain the stability of the internal environment. Immunity is low and vulnerable to disease. Improving human immunity is the basis for overcoming disease.

 Microorganisms such as bacteria and fungi are widely found in the natural environment in which we live, and also in the body surface and body cavity of the human body. Under normal circumstances, these bacteria are generally harmless to the human body, and some of the bacteria are even beneficial. They form a complex interdependent and mutually constrained micro-ecological system with the human body and the external environment. The intestinal flora is an important part of the intestinal defense barrier, and a balanced intestinal flora is important for human health.

 However, in modern society, with the improvement of the rhythm of life and the irregular state of diet, as well as due to aging, malnutrition, frail elderly, intestinal and other systemic acute and chronic diseases, long-term use of antibiotics, hormones, antineoplastic drugs , radiotherapy, chemotherapy and other reasons, often cause damage to the human intestinal micro-ecological system, causing gastrointestinal dysfunction and intestinal flora imbalance, digestive and absorption functions are weakened, seriously affecting the body's immune system function, resulting in low immune function , causing translocation of flora, inducing endogenous infections, causing pathological changes, leading to a variety of diseases, such as gastrointestinal infections, constipation, irritable bowel syndrome, inflammatory bowel disease.

 Most people generally use the treatment method, and most of them use western medicine. However, for gastrointestinal diseases, gastrointestinal diseases can be relieved, but western medicine generally stimulates the gastrointestinal tract. The gastrointestinal function of patients with gastrointestinal diseases is weak. The side effects are quite large. It is easy to damage the balance of the body after prolonged use, which may aggravate the condition and may cause other diseases to breed. At present, health foods for improving gastrointestinal function mainly include health foods for regulating gastrointestinal flora, health foods for laxatives, gastric mucosa, and health foods for promoting digestion and absorption. However, these health foods have a single function and effect, and only a certain function is promoted or changed, and no further research is carried out in a deeper and broader field.

 However, current health food products still need to be improved. Summary of the invention

The present invention is directed to solving at least some of the above technical problems or at least providing a useful commercial choice. To this end, it is an object of the present invention to provide an edible composition which simultaneously has a regulatory effect of improving gastrointestinal function and enhancing human immunity. Thus, in one aspect of the invention, the present invention provides an edible composition comprising, according to an embodiment of the present invention, 40 to 120 parts by weight of Inca; 10 to 90 parts by weight Astragalus; 10 to 80 parts by weight of hydrazine; 30 to 100 parts by weight of inulin; 30 to 90 parts by weight of corn pollen; 10 to 90 parts by weight of slag leaves and 20 to 120 parts by weight of functional sugar.

 The inventors have found that certain Chinese medicines and food ingredients mainly include amino acids, polysaccharides, vitamins, various trace elements and other organic and inorganic substances. Studies have shown that these Chinese medicines and many components in foods promote the growth metabolism of bacteria, promote the proliferation of gastrointestinal probiotics, inhibit the growth of pathogenic bacteria, and play an important role in the intestinal flora. At the same time, probiotics can also promote the absorption and utilization of these traditional Chinese medicines and foods, improve the function of the human gastrointestinal tract, enhance the body's immunity, and enhance the body's ability to resist disease.

 After intensive creative labor and optimization work, the inventor of the present application unexpectedly discovered that an edible composition composed of a mixture of Inca, Astragalus, Poria, Inulin, Corn Pollen, Cloth Leaves and Functional Sugar is improving. The function of the gastrointestinal tract and the function of enhancing the immunity of the human body are obvious, and the combination of the components of the edible composition in improving the function of the gastrointestinal tract and enhancing the immunity of the human body is superior to the effect of the single component, and has obvious effects. Synergies.

 Inca (P/lessiii vo/ b fc L.Jnca Peanut, sacha inchi) is a large vine, also known as Inca peanut, South American vine, Star vine, and Meito fruit. The perennial oil plant, native to the Amazonian rainforest of South America, was originally transformed from the Incas to the wild, and has been used by local indigenous people for thousands of years in the Inca region of South America. When planted in the same year, the fruit can be hung. The seeds are rich in oil, protein, amino acids, vitamin A, vitamin E and some other trace elements. Inca oil contains extremely rich unsaturated fatty acids (ω-3, ω-6, ω- 9), as well as vitamins, strontium and protein, and the content of three unsaturated fatty acids is as high as 92% or more. Inca fruit is rich in essential fatty acids a-linolenic acid, the mother of omega-3 unsaturated fatty acids, the most basic and primitive substance in the evolution of life. (-Linolenic acid, as the core substance of life, is one of the important components of human tissue cells. It is involved in the synthesis and metabolism of phospholipids in the human body, and is transformed into the vital activity factors DHA and sputum necessary for the body. When ct-linolenic acid is insufficient in human body When the immune system is low, it will cause various diseases. When the body is supplemented with a sufficient amount of ct-linolenic acid, the symptoms of these diseases will be significantly improved.

 Astragalus membranaceus is the dry root of the leguminous plant Astragalus. The plant is mainly distributed in the northeast, north and northwest of China. The chemical constituents of Astragalus are mainly monosaccharides, polysaccharides, saponins, flavonoids, amino acids and trace elements. Force, anti-fatigue, anti-mutation, liver protection, inhibition of osteoclasts, can prevent the immunosuppressive effect of hydrocortisone, and can enhance the phagocytic function of macrophages and promote antibody synthesis; have detoxification effect, can strengthen normal The heart contraction, which has a strong heart effect on the failing heart, can dilate the blood vessels of the coronary vessels and kidneys and dilate the blood vessels at the peripheral end of the body.

It contains polysaccharides, glucose, protein, amino acids, organic acids, fats, lecithin, adenine, choline, ergosterol, various enzymes and potassium salts. It can enhance the body's immune function, diuretic effect, calming and protecting the liver, inhibiting the occurrence of ulcers, lowering blood sugar, and resisting radiation. It can also be used as an important therapeutic ingredient for glutinous cakes, glutinous rice cakes and alcoholics. It can be eaten regularly to moisturize the spleen, help digestion, and strengthen the body. In short, 茯苓 The nature is peaceful, the water is good without hurting the righteousness, the spleen and the stomach are spleen, the heart is calming and calming, the body immunity can be effectively enhanced, the digestion can be enhanced, and the body can be strengthened.

 Inulin is mainly distributed in Compositae, with the highest content in chicory. Inulin is the highest quality, pure natural, soluble fructan mixture found by humans to date. Inulin was approved by the Ministry of Health as a new resource food in 2009. Inulin has the characteristics of low calorie, water solubility and the like, and enhances the proliferation of bifidobacteria, lowers blood sugar and blood lipids, restores gastrointestinal function, and enhances calcium absorption. Feeding inulin every day can greatly increase the number of beneficial bacteria in the colon, reducing pathogens and spoilage bacteria such as Salmonella, Listeria, Staphylococcus aureus, and coliforms. The mechanism is that the inulin is not digested and absorbed, but directly enters the large intestine and is preferentially used by bifidobacteria to produce acetate and lactate, which lowers the pH value of the large intestine, thereby inhibiting the growth of harmful bacteria.

 Corn is the third largest crop in China, and the northeast is the main producing area of corn in China. The corn pollen resources are abundant. Corn pollen has high nutritional value, large individual size, large yield and easy harvesting. Corn pollen is rich in protein, sugar, amino acids, nucleic acids, vitamins and other nutrients. After the corn pollen is broken, it can separate and extract the active ingredients such as polysaccharides and flavonoids. It can promote the development of immune organs of the spleen, bones, lymph nodes and thymus, enhance the activity of immune cells, improve the body's ability to fight bacteria and viruses, and have anti-radiation and anti-cancer effects. It can enhance immunity, promote growth and development, lower blood pressure and other health care. Features. At the same time, corn pollen can provide a variety of nutrients needed by the human body, and it also has a good auxiliary effect for diseases caused by lack of certain nutrition. Therefore, corn pollen has a wide range of clinical applications and is a supplement to various diseases and a supplement to daily nutrition. Corn pollen can be processed into health drinks such as oral liquid, pollen capsules, pollen beverages and pollen yoghurt, as well as functional foods such as pollen bread and pollen noodles. Corn pollen is rich in vitamin B group substances, among which vitamin B1 can stimulate the production of digestive enzymes and help digestion; vitamin B6, minerals and methionine can treat intractable constipation and diarrhea; corn pollen also contains natural Antibiotics and growth-promoting substances can control the growth of coliforms and salmonella, repair the parts of gastrointestinal damage, and thus have magical effects on the treatment of gastric and duodenal ulcers and perforations.

 The slag leaves are the rags of the genus Eucalyptus. The leaves of Microcos paniculata. can be harvested all year round. They are usually picked in summer and autumn, and the stems are removed. The slag leaves are light, slightly acidic, and flat. They have the effects of clearing heat and eliminating stagnation, dampness and yellowing, and phlegm. They are mainly used for colds, heatstroke, loss of appetite, indigestion, dampness and heat stagnation, abdominal pain, and less food. Diarrhea, damp heat, jaundice, etc. The slag leaves contain alkaloids, organic acids, sugars, phenols and tannins. Since ancient times, the slag leaves have been widely used in the folks of Lingnan in China. Folk slag leaves are used as summer drinks, which have thirst-quenching and appetizing effects.

 According to an embodiment of the present invention, a preferred edible composition comprises: 70 to 110 parts by weight of Inca; 30 to 70 parts by weight of xanthine; 20 to 60 parts by weight of hydrazine; 50 to 80 parts by weight of inulin; ～80 parts by weight of corn pollen; 30 to 70 parts by weight of cloth slag leaves and 40 to 100 parts by weight of functional sugar. Thereby, the regulating effect of the edible composition for improving the function of the stomach and the intestine and enhancing the immunity of the human body can be further improved.

According to an embodiment of the invention, the most preferred edible composition comprises: 90 parts by weight of Inca; 60 parts by weight Astragalus; 50 parts by weight of enamel; 70 parts by weight of inulin; 70 parts by weight of corn pollen; 50 parts by weight of cloth slag leaves and 70 parts by weight of functional sugar. Thereby, the regulating effect of the edible composition for improving gastrointestinal function and enhancing human immunity can be further improved.

 According to an embodiment of the present invention, the type of functional sugar which can be used in the edible composition of the present invention is not particularly limited. According to a specific example of the present invention, the functional sugar that can be employed is at least selected from the group consisting of konjac glucomannan, yeast glucan, chitooligosaccharide, oligofructose, galactooligosaccharide, xylooligosaccharide, and oligo-isomaltose. One. Thereby, the regulating effect of the edible composition for improving gastrointestinal function and enhancing human immunity can be further improved.

 Konjac glucomannan is a high molecular weight water soluble polysaccharide. China and Japan cultivated and consumed konjac since ancient times. In 1997, the US FDA approved konjac glucomannan as a food additive. On February 16, 1998, the Chinese Ministry of Health officially listed Konjac as the new food resource list for general food management. On November 4, 1998, the EU officially approved the use of konjac glucomannan in food. Since konjac glucomannan has many excellent properties, it is widely used as a food and beverage additive.

 Yeast glucan is derived from Saccharomyces cerevisiae. It has a variety of physiological activities due to its special structure, and it has been widely used in the GRAS (usually considered safe) in the US FDA. In a variety of foods. In China, the Ministry of Health of the People's Republic of China 2010 No. 9 Announcement approved yeast glucan as a new resource food, enabling it to be used in various foods. As a dietary fiber, yeast glucan can be decomposed by intestinal bacteria, promote gastrointestinal motility, stimulate the secretion of digestive juice, and have the function of assisting digestion; it can increase the peristalsis of the intestine and promote defecation, thus effectively preventing constipation; Absorption of calcium, magnesium and zinc by the intestines. The unique β-(1→3) framework of yeast glucose has a strong immunomodulatory activity. Can significantly improve human immunity.

 Chitosan oligosaccharide is a product of polymerization degree 2-10 after degradation of chitosan. Its water solubility is better than that of chitosan, and it is easily absorbed and utilized. The absorption rate of chitosan oligosaccharide in human body is nearly 100%, and the biological activity is more than chitosan. Stronger. It inhibits tumor cell growth, strengthens liver function, enhances immunity, prevents stomach ulcers, lowers blood pressure, blood sugar, blood lipids, cholesterol absorption and antibacterial effects.

 Oligofructose is widely found in onions, honey, aloe vera and wheat plants, but its content is extremely low. At present, fructose transferase produced by Aspergillus can be used in sucrose to produce oligofructose on a large scale. Oligosaccharide fructose can selectively proliferate bifidobacteria, which is metabolized by bifidobacteria to produce acetic acid and lactic acid, which makes the intestinal tract acidic, inhibits the proliferation of harmful bacteria, and promotes intestinal peristalsis. Oligofructose also has many important physiological functions such as regulating human immunity and lowering blood lipids.

Oligogalactose is a functional oligosaccharide with natural properties. The Ministry of Health announced in 2008 No. 20 of the Ministry of Health that it is a new resource food, which has strong acid resistance and heat resistance and will not be in the process. The high temperature sterilization and the decomposition of human stomach acid lose their original characteristics. The galactooligosaccharide can be effectively utilized by both Bifidobacterium bisporus and C. lactis. Oligosaccharide is the only functional sugar that can be utilized by the eight beneficial bacteria in the human intestine, and can inhibit the growth and reproduction of harmful bacteria in the human intestine. As a new functional food, galacto-oligosaccharide has broad market prospects in China. Xylo-oligosaccharide is one of the most potent varieties of proliferating bifidobacteria in polymeric sugars. The Ministry of Health announced in 2008 No. 12 of the Ministry of Health that it is a new resource food. Its efficacy is nearly 20 times that of other polymeric sugars. There is no enzyme for hydrolyzing xylooligosaccharides in the human gastrointestinal tract, so it can be directly used in the large intestine to be used by bifidobacteria to promote the proliferation of bifidobacteria. Organic acids. Reduce the pH of the intestines, inhibit the growth of harmful bacteria, and proliferate the probiotics in the intestines. Due to the strong adsorption capacity of xylooligosaccharides on pathogenic bacteria such as Escherichia coli and Enterobacter elegans, the attached pathogenic bacteria can be excreted through the intestinal tract, thereby preventing the disease from clustering in the intestinal tract and achieving the purpose of preventing diarrhea, thereby achieving health care effects. .

 According to an embodiment of the present invention, the form of the edible composition is not particularly limited as long as it can be used for consumption. According to a specific example of the invention, the comestible composition may be in the form of a capsule, tablet, granule or granule. Thereby, it is convenient for human consumption, thereby improving the regulating effect of the edible composition to more effectively improve the function of the gastrointestinal tract and enhance the immunity of the human body.

 In a second aspect of the invention, the invention proposes a food product. According to an embodiment of the invention, the food product comprises the edible composition described above. According to an embodiment of the present invention, the form of the food is not particularly limited as long as it can be used for eating. According to a specific example of the invention, the food product may be in the form of a capsule, a tablet, a granule or a granule. Thereby, it is convenient for human consumption, thereby improving the regulating effect of the edible composition to more effectively improve the function of the gastrointestinal tract and enhance the immunity of the human body. It will be understood that the foregoing description of the features and advantages of the edible compositions applies to the food product and will not be described again.

 Thus, the food provided by the present invention can be used as a health food, which can be made into a pharmaceutically acceptable capsule, tablet, or granule by a conventional process.

 To this end, in a third aspect of the invention, the invention proposes a method of preparing a food product. According to an embodiment of the present invention, the method comprises: providing the edible composition described above, wherein the Inca, Astragalus, Poria, Inulin, Corn Pollen, Cloth Leaves, and Functional Sugar are in a granular form; The comestible composition is subjected to a molding process to obtain the food product. According to an embodiment of the invention, the particles have a particle size of from 100 to 300 mesh. According to a specific example of the invention, the shaping process further comprises: forming the comestible composition in the form of a capsule, tablet, granule or granule. It will be understood that the foregoing description of the characteristics and advantages of the edible composition and the food product applies to the method and will not be described again.

The health food of the present invention is subjected to a safety evaluation test, including a mouse acute toxicity test, a mouse genotoxicity test, a rat 30-day feeding test, and the above test indicates: the health food of the present invention, the acute oral cavity of the mouse The toxicity test is more than 10 g/kg_bw, which is safe and non-toxic. In the genotoxicity test, the Ames test result is negative, the mouse bone marrow polychromatic erythrocyte micronucleus test result is negative, and the mouse sperm abnormality test result is negative, indicating The product has no mutagenic effect; the results of the 30-day feeding test in rats indicate that the health food of the present invention has been subjected to a 30-day feeding experiment in rats, and has important indexes such as overall health status, physiological and biochemical functions and organ histomorphology of the rats. No significant impact. Table The health food soft capsule according to the invention is safe to take.

 The health food of the invention has the function and effect of enhancing immunity, and the health food of the invention has better effect on enhancing immunity than the single component of astragalus, oligofructose, chitosan oligosaccharide and yeast dextran. Effect. The experimental results of the health-improving function of the health food of the present invention showed that there was no significant difference in body weight, thymus/body weight ratio, and spleen/body weight ratio of each batch of mice. In the mouse antibody-producing cell assay, the serum hemolysin assay, and the mouse carbon clearance assay, the results were significantly different.

 Bifidobacteria are representative of beneficial bacteria, can inhibit the growth of harmful bacteria, and maintain the normal micro-ecological environment in the intestine. Increasing the number of bifidobacteria in the human gut can significantly improve the gastrointestinal function and health of the human body. The animal experiment for regulating the function of the intestinal flora by the health food of the present invention, and the human food experiment for regulating the function of the intestinal flora can be seen that the health food of the present invention has the function of regulating the intestinal flora. . The present invention can significantly stimulate the growth and increase of the number of beneficial bacteria (such as bifidobacteria) in the human intestinal tract, and significantly reduce the number of harmful bacteria such as Clostridium perfringens. Moreover, the number of Bifidobacteria, Enterobacteriaceae, and the number of Clostridium perfringens in the human intestinal tract after taking Inca soft capsules were lower than those after taking Inca fruit oil and taking Xylooligosaccharides. The effect of the subject after the capsule is more obvious, that is, the health care function of the health food of the present invention is superior to the effect of the single component.

 From the test of the therapeutic effect of the health food of the present invention on constipation patients, the present invention has the function of improving gastrointestinal function, and can function as a laxative and prevent constipation, and no adverse reaction is observed during the administration.

 In a fourth aspect of the invention, the invention provides the use of the above edible composition in the preparation of a formulation. According to a specific embodiment of the present invention, any edible preparation can be prepared by using the above edible composition, for example, a pharmaceutically acceptable dosage form such as a capsule, a soft capsule, a tablet, or a granule can be prepared. According to a specific embodiment of the present invention, the above preparation can be used for improving gastrointestinal function and enhancing human immunity and the like. Thus, a dosage form can be prepared by using the above edible composition for exerting its function of improving gastrointestinal function, enhancing human immunity, and the like.

 The beneficial effects of the invention are:

 1. All the raw materials in the health food according to the present invention are natural, natural, safe and reliable, and the raw materials are widely available. The compatibility of the prescriptions is scientific and reasonable, the curative effect is exact, the preparation process is simple, and the storage and application are safe. Production costs are low.

 2. The inventor of the present application discovered through accidental labor and optimization work: a health food consisting of a mixture of Inca, Astragalus, Poria, Inulin, Corn Pollen, Cloth Leaves and Functional Sugar, The combination of functions and functions has obvious health care functions and synergistic effects for simultaneously improving the gastrointestinal tract and enhancing human immunity, and the combined effect of the invention in improving gastrointestinal function and enhancing human immunity is better than single The effect of the ingredients.

3. The health food of the invention not only improves the human immunity, but also improves the distribution of the intestinal flora of the human body, significantly stimulates the growth and increase of the number of beneficial bacteria (such as bifidobacteria) in the human intestinal tract, and reduces the harmfulness in the intestinal tract. Bacteria The number of Clostridium perfringens plays a bacteriostatic effect, and at the same time achieves the health benefits of enhancing immunity, regulating intestinal flora, laxative, and preventing constipation.

 4. In the health food granules and soft capsules of the present invention, the raw materials are mixed and pulverized into fine powder of 100-230 mesh, which is favorable for uniform dispersion of the active ingredients in the raw materials, and is convenient for absorption in the gastrointestinal tract of the human body. Moreover, the use of Inca fruit oil as a dispersing agent for soft capsules is advantageous for soft capsule molding, and the soft capsule dosage form is also advantageous for uniformly dispersing other active ingredients in the oil to facilitate absorption by the human body.

 5. The health food of the invention has obvious efficacy, good safety, stable quality, long-term preservation of the product, and provides a new choice for daily health care.

 The advantages of the invention will be set forth in part in the description which follows.

 detailed description

 The following examples are intended to further illustrate the invention and are not intended to limit the scope of the invention. It should be noted that the raw materials used in the following examples are commercially available unless explicitly stated.

 Example 1-12: The health food formula of the present invention

 Table 1 Health food formula of Examples 1-12 of the present invention (weight unit of raw materials: parts by weight)

 ^Example Implementation Implementation Implementation Implementation Implementation Implementation Implementation Implementation Implementation Implementation Implementation Material Example 1 Example 2 Example 3 Example 4 Example 5 Case 6 Case 7 Case 8 Case 9 Case 10 Case 11 Example 12 Inca 40 70 70 90 120 90 110 120 100 90 110 90 Astragalus 90 50 70 60 60 50 10 80 60 60 30 70 茯苓70 60 80 50 50 10 80 70 70 50 20 70 Inulin 40 80 60 70 50 80 100 30 50 70 90 50 Corn pollen 60 30 60 70 90 80 50 60 90 70 70 60 slag leaves 40 70 90 50 10 60 60 60 40 50 70 50 Konjac glucomannan 100 25 30

 Yeast dextran 80 —— 30 70 25 ——

 Redundant sugar 70 30 60 oligofructose 40 40 oligogalactose 40 20 40 20 xylooligo 60 20

 200 140 230 170 200 200 120 170 140

 Smash into 200 mesh, 170 mesh, 230 mesh

 @目 @ @ @

 Soft rubber soft rubber soft rubber soft gel dosage form tablets granules granules granules tablets granules tablets

Cystic sac According to the above table, the components of the health food according to the present invention can be made into capsules, tablets, or granules in pharmacy by a conventional process.

 The preparation process of the granule is listed below.

 For the health food granules described in Example 4 (hereinafter referred to as Inca granules), the preparation process is as follows:

 1. Weigh 90 parts by weight of Inca fruit, remove the Inca fruit with a peeling machine, dry it, and set aside;

 2. Weigh 60 parts by weight of Astragalus, 50 parts by weight of enamel, 70 parts by weight of inulin, 70 parts by weight of corn pollen, 50 parts by weight of slag leaves, and 70 parts by weight of chitosan oligosaccharides, and the above seven raw materials are mixed and crushed. In the machine, the mixture is pulverized for 30 minutes, and the fine powder of 170 mesh is dispensed.

 Health care function: regulate intestinal flora, enhance immunity

 Suitable for people: those with intestinal dysfunction and those with low immunity

 Not suitable for the crowd: None

 How to eat and how to eat: 2 times a day, 1 bag each time

 Product specifications: 5g / bag

 Shelf life: 24 months

 Storage method: sealed, kept in a cool dry place

 Note: This product is not a substitute for drugs

 The preparation process of the capsules is listed below.

 For the health food soft capsule (hereinafter referred to as Inca soft capsule) described in Example 10, the preparation process is as follows:

1. Weigh 60 parts by weight of Astragalus, 50 parts by weight of enamel, 70 parts by weight of inulin, 70 parts by weight of corn pollen, 50 parts by weight of slag leaves, 30 parts by weight of konjac glucomannan, and 40 parts by weight of galactooligosaccharide. The six kinds of raw materials are mixed and put into a pulverizer, mixed and pulverized for 30 minutes to form a fine powder of 200 mesh, and used;

 2. Weigh 90 parts by weight of Inca fruit, peel the Inca fruit with a peeling machine, dry it, and cold-press the fruit to obtain the printing fruit oil. Mix the Indo fruit oil and the appropriate amount of soybean oil in the ingredient tank. Stir, and add the 200 mesh fine powder obtained in the above step (1), stir for 30 minutes, mix the liquid mixture and grind the mixture for three times. After the grinding, vacuum the air bubbles to remove the air bubbles, and prepare the content material liquid for use;

 3. Put gelatin, glycerin, hydration glue, and tape. The content material liquid is placed in a soft capsule pilling machine, filled into soft capsules, and then put into a drum drying device for drying by blowing, so that the soft capsules are hardened, and then subjected to ethanol sterilization and scrubbing, by controlling the temperature and humidity of the drying chamber ( 50% or less), the capsule shell moisture and ethanol are naturally evaporated, the drying time is not less than 20 hours, until the surface of the capsule is dry and smooth, slightly elastic, and the drying is completed. Finally, the unqualified soft capsules such as the appearance and the joints are sorted and discarded, and the selected qualified soft capsules are packaged in the form of bottles or blister sheets, that is, the finished products (referred to as Inca soft capsules). Health care function: regulate intestinal flora, enhance immunity

Suitable for people: those with intestinal dysfunction and those with low immunity Not suitable for the crowd: None

 How to eat and how to eat: 3 times a day, 3 capsules each time

 Product specifications: l.Og / grain

 Shelf life: 24 months

 Storage method: sealed, kept in a cool dry place

 Note: This product is not a substitute for drugs. The beneficial effects of the present invention are further illustrated by experiments below.

 Example 13: Determination of acute toxicity by oral administration to rats

 Acute toxicity tests were performed using 6-week-old SD rats without specific pathogens (SPF).

 The health food prepared in Example 4 was suspended in a 0.5% methylcellulose solution, and orally administered to 5 SD rats in each group at a dose of lg/kg, 5 g/kg, and 10 g/kg, respectively. Rats were tested for death, clinical symptoms, and weight changes, and blood tests and blood biochemical tests were performed. At autopsy, any abnormalities in the gastrointestinal tissue of the chest and abdomen were visually examined.

 The results showed that the health food described in this example did not cause any specific clinical symptoms, weight changes or death, and blood tests, blood biochemical tests and autopsy did not change. Therefore, since the dose up to 10 g/kg does not cause any poisoning change in the rat, it can be judged that the median lethal dose (LD50) is much larger than 10 g/kg, and the health food of the present embodiment is evaluated as a safe non-toxic substance.

 Example 14: Study of enhancing immunity function

 First, the test materials

 Experimental animals: BALB/C 1 month old secondary mice, male and female, weighing 20±2g, in good health, provided by Experimental Animal Center of Wuhan University Medical College, production license number: SCXK (E) 2008-0004. Each batch of animals was randomized.

 In this example, the Indo-Chong granule prepared in Example 6 was used. The recommended dose was 250 mg/kg.BW (body weight) per day, and 0.5, 1, and 2 times of the mice were recommended as low dose group C125 mg/kg. .BW), medium dose group (250 mg/kg. BW), high dose group (500 mg/kg. BW).

 Set 4 positive control groups,

 The positive control group 1 is the Astragalus polysaccharide capsule (the main raw materials: Astragalus, oligo-isomalt, Inner Mongolia Shuangqi Pharmaceutical Co., Ltd., Guoshijianzi G20040082),

 Positive control group 2 is oligofructose oral solution (main raw materials: oligofructose, Zhuhai Shengyuan Biotechnology Co., Ltd., Guoshijianzi G20050336),

 The positive control group 3 was chitosan oligosaccharide capsules (main raw materials: chitosan oligosaccharide, Xiamen Lanwan Technology Co., Ltd., Guoshijianzi G20110158),

The positive control group 4 is yeast glucan capsule (main raw material: yeast glucan, Nanjing Dayuan Beauty Health Care Co., Ltd. Division, Guoshijianzi G20110445).

 Other major reagents are: sheep red blood cells (SRBC), Hank's solution, guinea pig serum, ink.

 The preparation method of Hank's liquid:

 (1) Stock solution:

NaCl: 80.00g, KC1: 4.00g, Na ₂ HP0 ₄ 12H ₂ 0: 1.52 g, KH ₂ PO ₄ : 0.60g, glucose: 4.0g, 0.4% phenol red liquid: 50.00mL, double distilled water plus constant volume to lOOmL, autoclaved at 115 °C for 15 min, stored frozen.

 (2) Working fluid:

9 volumes of double-distilled water were added to the stock solution and autoclaved at 115 °C for 15 min. When used, the pH was adjusted to 7.2-7.4 (the solution was orange-red) with a sterile 5.6% NaHC0 ₃ solution.

 Preparation of physiological saline: 9.00 g of NaCl was dissolved in 991 g of double-distilled water to obtain a 0.9% NaCl solution.

 Second, the test method

 The test was performed by gavage. The stomach was administered once a day, and the blank control group was filled with the same volume of distilled water. Each group of mice was continuously administered with the test substance for 30 days, and each index was measured.

 2.1 Effects on body weight, thymus/body weight, spleen/body weight of mice

 The mice were sacrificed by cervical dislocation 30 days later and weighed. The thymus and spleen were taken, and the thymus and spleen weights were weighed separately, and the thymus/body weight value and the spleen/body weight value were measured.

 2.2 Effect on mouse antibody-producing cells (PFC) (Measurement of antibody-producing cells, hemolytic plaque assay, is a method for detecting single antibody-forming cells (plasma cells) in vitro)

Each mouse was immunized by intraperitoneal injection of 0.2 mL of 2% (v/v) SRBC. 5 days after immunization, the mouse spleen is made to take a cell concentration of spleen cells was 5x l0 ⁶ cells / mL. Dissolve the agarose to make a 1% solution, incubate in a 48 ° C water bath, mix with an equal amount of 2 times the concentration of Hank's solution, and dispense into a small tube, 0.5 mL per tube. Add 0.05 mL of 10% SRBC and O.OlmL spleen cell suspension, mix quickly and pour onto the slide. Incubate for 1 h in a 37 ° C incubator, add complement (guinea pig serum) to the slide trough, and incubate for 1.5 h. Count plaques.

 2.3 Effect on the production of hemolysin antibody in mice (measurement of serum hemolysin)

 Each mouse was immunized by intraperitoneal injection of 0.2 mL of 2% (v/v) SRBC. After 5 days of immunization, the eyeballs were taken from the centrifuge tube, placed for 1 h, centrifuged at 3000 rpm for 5 minutes, and serum was collected. The serum was diluted 400-fold with physiological saline, and diluted mouse serum 1.0 mL, 10% (v/v) SRBC 0.5 mL, and complement (diluted with physiological saline 1:10) 1.00 mL were sequentially added. A serum-free control tube replaced with physiological saline was also provided. After setting the water bath at 37 ° C for 20 minutes, the reaction was stopped at 0 ° C for 30 minutes, and centrifuged at 3000 rpm for 5 minutes. The supernatant was taken to 1.0 mL, and the optical density value was measured at a wavelength of 540 nm of a spectrophotometer.

 2.4 Effects on carbon clearance in mice

Each mouse was injected with 4 times diluted ink in the tail vein, 0.1 mL/10 g body weight. Time is counted immediately after the ink is injected. 0.02 mL of blood was taken to 2.0 mL of 0.1% Na ₂ C0 ₃ solution (ie, lg/L) at 1 minute and 10 minutes after injecting the ink, respectively. The optical density value was measured at a wavelength of 600 nm using a Na ₂ CO ₃ solution as a control. The liver and spleen were weighed. The phagocytic index ((X) is used to indicate the ability of the mouse to clear the carbon.

 Third, the test results

 3.1 Determination of body weight, thymus / body weight, spleen / body weight

 The effects of each test substance on the body weight, thymus/body weight ratio, and spleen/body weight ratio of the mice are shown in Tables 2, 3 and 4.

 Table 2 Effect of each test substance on body weight of mice

 Dosage number of animals

 Group Weight before experiment (g) P value Weight after experiment (g) P value

 (mg/kg-bw) (only)

 Blank control group 0 48 19.5±1.9 - 23.5±2.7 - positive control group 1 1 capsule 48 19.4±1.7 0.8524 23.0±2.9 0.9006 positive control group 2 0.5mL 48 19.5±1.8 0.4983 23.1±3.0 0.7759 positive control group 3 group 1 48 19.3±1.8 0.7781 23.3±2.7 0.6210 Positive control group 4 1 capsule 48 19.2±1.7 0.4850 23.2±2.8 0.5547 Low dose group 125 48 19.5±1.7 0.8065 23.4±3.0 0.6884 medium dose group 250 48 19.4±1.8 0.7251 23.3±2.9 0.6241 high Dosage group 500 48 19.5±1.8 0.8559 23.2±2.7 0.7997 It can be seen from Table 2 that the mice were given different doses of the test substance orally, and after 30 days, the low, medium and high dose groups were blank control group and positive control. There was no significant difference in body weight between the groups (P>0.05), that is, the mice fed three low, medium and high dose groups and four positive control groups had no effect on the body weight of the mice.

 Table 3 Effect of test substance on mouse thymus/body weight ratio

Group Ll amount (mg/kg 'bw) number of animals (only) thymus / body weight ratio fe / g) P value blank control group 0 12 0.0017 ± 0.0004 - positive control group 1 1 capsule 12 0.0019 ± 0.0003 0.4042 positive control 2 Group 0.5mL 12 0.0018±0.0004 0.4631 Positive control 3 group 1 capsule 12 0.0017±0.0004 0.3856 Positive control 4 group 1 capsule 12 0.0018±0.0003 0.3213 Low dose group 125 12 0.0018±0.0004 0.4570 Medium dose group 250 12 0.0018±0.0004 0.3687 High dose Group 500 12 0.0018±0.0003 0.4049 It can be seen from Table 3 that after 30 days of oral administration of different doses of the test article, there was no significant difference in thymus/body weight ratio between the dose groups (P>0.05). The mice were fed a sample pair of 3 dose groups and 4 positive control groups. Mice have no effect on thymus/body weight ratio<

 Table 4 Effect of test substance on spleen/body weight ratio in mice

 Group Ll amount (mg/kg 'bw) number of animals (only) thymus / body weight ratio fe / g) P value blank control group 0 12 0.0043 ± 0.0006 - positive control group 1 1 capsule 12 0.0040 ± 0.0008 0.7028 positive control 2 Group 0.5mL 12 0.0039±0.0006 0.3358 Positive control 3 group 1 capsule 12 0.0038±0.0005 0.1756 Positive control 4 group 1 capsule 12 0.0041±0.0006 0.3047 Low dose group 125 12 0.0040±0.0004 0.3361 Medium dose group 250 12 0.0042±0.0005 0.2273 High dose Group 500 12 0.0039±0.0005 0.4546 It can be seen from Table 4 that after 30 days of oral administration of different doses of the test article, there was no significant difference in spleen/body weight ratio between the dose groups (P>0.05). Samples fed to the mice in three dose groups and four positive control groups had no effect on the spleen/body weight ratio of the mice.

 3.2 Antibody-producing cells (PFC) determination results

 The antibody-producing cell (PFC) test results are shown in Table 5.

 Table 5 Effect of test substance on the number of mouse antibody-producing cells

 Group Ll amount (mg/kg 'bw) Number of animals (only) Number of antibody-producing cells (x±s) P value blank control group 0 12 72±22 - Positive control group 1 1 capsule 12 89±19 0.0452 Positive control 2 groups 0.5mL 12 83±23 0.1954 positive control 3 groups 1 capsule 12 83±21 0.2019 positive control 4 group 1 capsule 12 85±22 0.1686 low dose group 125 12 92±21 0.0341 medium dose group 250 12 99±20 0.0408 high Dosage group 500 12 90±21 0.0687 It can be seen from Table 5 that after oral administration of different doses of the test substance to the mice for 30 days, compared with the blank control group, the positive control

There was a significant difference in the number of PFCs between the 1 group and the low and middle dose groups (P<0.05), indicating that the high dose group and the three positive control groups had no effect on the PFC of the mice, while the positive control group 1, the low dose group, and the middle dose group. It has a significant effect on mouse PFC.

 3.3 Determination of serum hemolysin

The results of measurement of serum hemolysin are shown in Table 6. Table 6 Effect of test substance on serum hemolysin in mice

Group Ll amount (mg/kg 'bw) number of animals (only) HC50 P value blank control group 0 12 115±28 - positive control group 1 1 capsule 12 141±36 0.1951 positive control group 2 0.5mL 12 139±31 0.3554 Positive control 3 groups 1 capsule 12 130±19 0.0246 Positive control 4 group 1 capsule 12 134±20 0.1739 Low dose group 125 12 154±20 0.0080 Medium dose group 250 12 166±19 0.0067 High dose group 500 12 148±21 0.0894 As can be seen from Table 6, after 30 days of oral administration of different doses of the test article, compared with the blank control group, the HC _{5Q of the} low dose group and the middle dose group were significantly different (P<0.01), and the positive control group 3 The HC _5Q was significantly different (P<0.05), indicating that the low-dose and medium-dose groups described in this example were able to significantly increase the serum hemolysin HC _{5Q in} mice, and the positive control group 3 significantly increased the mice. Serum hemolysin HC _5Q , while positive control group 1, positive control group 2, positive control group 4, high dose group had no effect on serum hemolysin HC _5Q .

 3.4 Mouse carbon clearance test results

 The results of the mouse carbon clearance test are shown in Table 7.

 Table 7 Effect of test substance on carbon profile of mice

Group Ll amount (mg/kg 'bw) number of animals (only) phagocytic index a (X ± S) P value blank control group 0 12 3.24 ± 0.39 - positive control group 1 1 12 4.26 ± 0.47 0.0351 positive control 2 Group 0.5mL 12 4.29±0.48 0.0492 Positive control 3 groups 1 capsule 12 3.56±0.53 0.2255 Positive control 4 groups 1 capsule 12 3.45±0.64 0.4390 Low dose group 125 12 3.86±0.49 0.0433 Medium dose group 250 12 4.52±0.58 0.0074 High dose Group 500 12 4.83±0.79 0.0088 As can be seen from Table 7, after 30 days of oral administration of different doses of the test article, the medium dose group and the high dose group of the health food of the present example were compared with the blank control group. The phagocytosis ability of the cells was significantly different (P<0.01). The low-dose group, the positive control group 1 and the positive control group 2 had significant differences in the phagocytic ability of mouse macrophages (P<0.05), and the other groups were small. The mouse carbon clearance ability has no effect. This indicates that the health food of the present embodiment has an effect of enhancing the phagocytic function of mononuclear macrophages, and can enhance non-specific immune function of mice. The results of experiments before and after improving the immunity function of the health food of the present example showed that there was no significant difference in body weight, thymus/weight ratio, and spleen/body weight ratio of each batch of mice. In the mouse antibody-producing cell assay, the serum hemolysin assay, and the mouse carbon clearance assay, the results were significantly different. According to the evaluation criteria, the health food of the present embodiment can be considered to have the function and effect of enhancing immunity, and the health food of the present embodiment is superior to the single component of jaundice, oligofructose, chitooligosaccharide, and yeast. The effect of the glycan.

 Example 15: Regulation of intestinal flora function

 According to the Ministry of Health's “Technical Specification for Health Food Inspection and Evaluation (2003)”, animal experiments and human feeding experiments were conducted to regulate the function of intestinal flora.

 First, the material

 Experimental animals: 50 male Kunming mice weighing 20±2 g, in good health, provided by the Experimental Animal Center of Wuhan University Medical College, production license number: SCXK (E) 2008-0004.

 The health food granules (hereinafter referred to as Inca granules) used in the present embodiment were prepared in the same manner as in Example 4, and were packed in 5 g/bag aluminum foil. The recommended eating method was 2 times a day, 1 bag each time.

 The health food soft capsule (hereinafter referred to as Inca soft capsule) used in the present embodiment is prepared by the method of Example 10, and has a specification of 1.0 g/granule. The recommended eating method is 3 times a day, 3 capsules each time.

 The human food test experiment added two positive control groups, which were:

 Positive control group 1: Inca fruit oil (from Huada Gene (Laos) Co., Ltd., batch number 20120301), 2 times a day, 5mL each time;

 Positive control group 2: xylooligosaccharide capsule (Shandong Longli Biotechnology Co., Ltd., Guoshijianzi G20041284), 2 times a day, 3 capsules each time;

 Second, the method

 2.1 medium and intestinal flora test methods:

 Bifidobacterium: BBL medium, 37 °C, animal experiment 72h anaerobic culture, human food test 48h anaerobic culture; Lactobacillus: LBS medium, 37 ° C, 48h culture;

 Enterobacter: EMB medium, 37 ° C, 24 h culture;

 Enterococcus: sodium azide - crystal violet - esculin culture medium, 37 ° C, animal experiment 24 h culture, human trial experiment 48 h + Li Guan.

 Clostridium perfringens: TSC medium, 37 ° C, 24 h anaerobic culture.

 2.2 Experimental methods for regulating intestinal flora:

50 male mice were randomly divided into 5 groups, 10 in each group, of which 1 group was the normal control group, and the other 4 groups were given lincomycin hydrochloride. The dosage was 60 mg/10g_bw for 3 days. After testing, the mice developed dysbacteriosis, and one group was randomly selected to be administered with normal saline as a natural recovery group, and the other three groups were administered with the granules of the present example. Divided into 0.5g/kg_bw, 2.5g/kg-bw 5g/kg_bw 3 dose groups. Once a day for 7 days. After the last 24 h of the test object, the mouse feces were aseptically taken to detect the number of intestinal flora, and the changes of Bifidobacterium, Lactobacillus, Enterococcus, Enterobacter, Clostridium perfringens before and after the experiment were compared. .

 2.3 human test experiment method:

 The subjects were randomly divided into 3 groups, and the subjects' faeces were aseptically taken before the subjects were tested, and the number of intestinal flora was examined.

 The first group of subjects took the Inca soft capsule of the present example, 3 times a day, 3 times each time, for 7 days;

 The second group of subjects took the positive control group 1 of Inca fruit oil, 2 times a day, 5mL each time;

 The third group of subjects took the positive control group 2 xylooligosaccharide capsules, 2 times a day, 3 capsules each time;

 Subjects were observed and recorded separately before and after eating. After the last 24 hours of the test, the stool of the subject was aseptically taken and the number of intestinal flora was detected.

 Third, the results

 3.1 Experimental results of the regulation effect of the health food granules of the present example on the intestinal flora of mice, see Table 8.

 Table 8 Test results of intestinal flora in mice with intestinal flora (X±S, n=10) logCFU/g

^ Bacillus lentus Enterobacter enterococcal gastrosporic group: normal control group 9.36 ± 0.88 8.86 ± 0.92 6.58 ± 1.45 6.44 ± 1.11 7.72 ± 0.98 8.82 ± 0.83 8.22 ± 0.70 8.21 ± 0.69 after oral administration of antibiotics <2 <2 Natural recovery group 8.25±0.24 8.24±0.35 8.85±0.42 6.79±0.46 8.13±0.67 Low dose group 8.91±0.55* 9.18±0.39** 8.74±0.50 ^Δ 6.23±0.62 7.27±0.55 medium dose group 9.31±0.37 ** 9.59±0.23** 9.17±0.32 ^ΔΔ 7.43±0.70 ^Δ 8.26±0.41 ^Δ high dose group 8.74±0.32* 8.93±0.22** 8.78±0.53 ^Δ 6.52±0.92 7.80±0.84 Note: (1) and natural recovery group Comparison *Ρ<0.05; (2) Compared with the natural recovery group **Ρ<0.01;

(3) ^Δ Ρ < 0.05 compared with the normal control group; (4) ^ΔΔ Ρ < 0.01 compared with the normal control group.

It can be seen from Table 8 that the number of Bifidobacteria, Lactobacillus, Enterococcus, Clostridium perfringens, and the number of bacteria in the intestine of the mice after administration of antibiotics was significantly lower than that of the normal control group, indicating that the intestinal flora of the mice Disorder. After oral administration of the test substance to the mice, the number of five bacteria in the intestine of the mice increased, and the number of enterobacteria increased significantly in the low dose group compared with the normal control group, and the difference was significant (Ρ<0.05). Compared with the natural recovery group, the number of bifidobacteria increased significantly, the difference was significant (ΡΟ.05), and the number of lactobacilli increased significantly, and the difference was extremely significant (Ρ<0.01). Compared with the normal control group, the number of Enterococcus and Clostridium perfringens was significantly increased in the middle dose group, the difference was significant (Ρ<0.05), and the number of Enterobacteriaceae was significantly increased. The difference was extremely significant (Ρ<0.01). Compared with the natural recovery group, the number of bifidobacteria and lactobacilli increased significantly, and the difference was extremely significant (Ρ<0.01). The number of enterococci and Clostridium perfringens increased significantly, and the difference was significant. Sexuality (P<0.05); the number of Enterobacteriaceae was significantly increased in the high-dose group compared with the normal control group, the difference was significant (P<0.05). Compared with the natural recovery group, the number of Lactobacilli increased significantly, and the difference was extremely significant. Sex (P<0.01).

 3. 2 Experimental results of human food test of soft food capsules of the present embodiment

 The changes in human intestinal flora before and after taking Inka soft capsules are shown in Table 3.

 9.03±0.58 8.36±0.85 5.18±1.43 6.24±1.25 6.56±1.58 before taking Inca fruit oil 10.05±0.55** 8.40±0.96 5.85±0.99** 6.15±1.33 4.80±1.42** After taking xylooligosaccharide capsules 10.36±0.48** 8.44±1.13 6.16±1.04** 6.09±1.35 3.98±1.35** After taking Inka soft capsule 11.32±0.37* 8.52±1.07 6.67±1.29* 6.01±1.49 3.20±1.29*

(1) Comparison after taking with *P<0.01

 (2) Comparison after taking with **P<0.05

 It can be seen from Table 9 that the number of Bifidobacteria and Enterobacteriaceae increased significantly after taking Inka soft capsules, and the difference was extremely significant (P<0.01). The number of Lactobacilli increased, and the difference was not significant ( P>0.05); Enterococcus had a decreasing trend, the difference was not significant (P>0.05); the number of Clostridium perfringens was significantly reduced, the difference was extremely significant (P<0.01). After taking Inca fruit oil and taking xylo-oligosaccharide capsules, the number of Bifidobacteria and Enterobacteriaceae increased significantly, the difference was significant (P<0.01); the number of Lactobacilli increased, the difference was not Significant (P>0.05); Enterococcus had a decreasing trend, the difference was not significant (P>0.05); the number of Clostridium perfringens was significantly reduced, the difference was significant (P < 0.01).

 Bifidobacteria are representative of beneficial bacteria, can inhibit the growth of harmful bacteria, and maintain the normal micro-ecological environment in the intestine. Increasing the number of bifidobacteria in the human gut can significantly improve the gastrointestinal function and health of the human body. The animal experiment of regulating the function of the intestinal flora by the above-mentioned Inka soft capsule and the human food test experiment of regulating the function of the intestinal flora can be seen that the health food of the embodiment has the function of regulating the intestinal flora, and the invention can significantly stimulate the human intestine The number of beneficial bacteria in the tract, Bifidobacteria, Enterobacter, and the number of harmful bacteria Clostridium perfringens were significantly reduced. Moreover, the number of Bifidobacteria, Enterobacteriaceae, and the number of Clostridium perfringens in the human intestinal tract after taking Inca soft capsules were lower than those after taking Inca fruit oil and taking Xylooligosaccharides. The effect of the subject after the capsule is more obvious, that is, the health care function of the health food of the present invention is superior to the effect of the single component.

 Example 16: Treatment of constipation effect test

According to the “Technical Specification for Health Food Inspection and Evaluation (2003)” of the Ministry of Health, after the in-depth effectiveness and safety study of the present invention, the present embodiment adopts the Indo-Chong agent (hereinafter referred to as Inca granule) prepared in the fourth embodiment. Treatment trials for patients with constipation. Test subject:

 50 patients with mild constipation were enrolled, aged 40-60 years; 50 patients with moderate constipation, aged 40-60 years; 50 patients with severe constipation, aged 40-60 years. Among them, mild constipation means 2-3 days of bowel movements, moderate constipation means 3-6 days of bowel movements, and severe constipation means more than 7 days of bowel movements or relies on laxatives for defecation, once or twice a day.

 experiment method:

 Treatment of constipation patients with Inca granules.

Patients with mild constipation took Inca granules for 7 days, taking 2 bags a day for the first three days, and then taking 1 bag every day for four days. Patients with moderate constipation took Inca granules for 7 days, taking 4 bags a day for the first three days, and then taking 2 bags a day for four days, brewing in warm water. Patients with severe constipation took Inca granules for 7 days, taking 6 bags a day for the first three days, and then 3 bags a day for four days.

 Test effect:

 In patients with mild constipation, the loose and loose stools were removed two to three times a day during the first three days of Inca granules, and constipation was significantly improved. After the reduction on the 4th to 7th day, one or two soft stools were discharged every day.

 In the first three days of taking Inga granules, 43 patients had loose or loose loose stools every day, 7 patients had loose stools once or twice a day, and after 4-7 days of reduction, Fifty patients had one or two soft stools per day.

 In the first three days of taking Yinka granules, 27 patients had loose or loose loose stools every day, 20 patients had loose stools once or twice a day, and the remaining 3 patients had bowel movements within 3 days. Constipation There was also improvement. After taking the dose on days 4-7, 48 patients had one or two bowel movements per day, and 2 patients had bowel movements once every 2 days. Patients with different degrees of constipation have been treated effectively.

 From the test of the therapeutic effect of the health food of the present embodiment on constipation patients, the product has the function of improving the function of the gastrointestinal tract, and can function as a laxative and constipation, and no adverse reaction is observed during the administration. In the description of the present specification, the description of the terms "one embodiment", "some embodiments", "example", "specific example", or "some examples" and the like means a specific feature described in connection with the embodiment or example. A structure, material or feature is included in at least one embodiment or example of the invention. In the present specification, the schematic representation of the above terms does not necessarily mean the same embodiment or example. Furthermore, the particular features, structures, materials, or characteristics described may be combined in a suitable manner in any one or more embodiments or examples.

 Although the embodiments of the present invention have been shown and described, it is understood that the foregoing embodiments are illustrative and not restrictive Variations, modifications, alterations and variations of the above-described embodiments are possible within the scope of the invention.

Claims

claims 1. An edible composition, characterized in that it contains: 40-120 parts by weight of Sacha Inchi; 10-90 parts by weight of Astragalus membranaceus; 10-80 parts by weight of Poria cocos; 30-100 parts by weight of inulin; 30-90 parts by weight of corn pollen; 10 to 90 parts by weight of cloth residue leaves; and 20-120 parts by weight of functional sugar. 2. The edible composition according to claim 1, characterized in that, comprising: 70 to 110 parts by weight of Sacha Inchi; 30-70 parts by weight of Astragalus membranaceus; 20-60 parts by weight of Poria cocos; 50-80 parts by weight of inulin; 50-80 parts by weight of corn pollen: 30 to 70 parts by weight of cloth residue leaves; and 40-100 parts by weight of functional sugar. 3. The edible composition according to claim 1, characterized in that, comprising: 90 parts by weight of Sacha Inchi; 60 parts by weight of astragalus: 50 parts by weight of Poria; 70 parts by weight of inulin; 70 parts by weight of corn pollen; 50 parts by weight of cloth residue leaves; and 70 parts by weight of functional sugar. 4. The edible composition according to any one of claims 1 to 3, characterized in that the functional sugar is selected from the group consisting of konjac glucomannan, yeast glucan, chitosan oligosaccharide, fructooligosaccharide, and low-glucomannan. At least one of polygalactose, xylo-oligosaccharide and isomaltooligosaccharide. 5. The edible composition according to any one of claims 1 to 4, characterized in that the edible composition is in the form of capsules, tablets, granules or granules. 6. A food, characterized in that it includes the edible composition according to claims 1 to 5. 7. The food according to claim 6, characterized in that the food is in the form of capsules, tablets, granules or granules. 8. A method of preparing food, characterized in that it includes: The edible composition according to any one of claims 1 to 5 is provided, wherein the Inchi Inchi, Astragalus, Poria, inulin, corn pollen, Buji leaves and functional sugar are in granular form; and subjecting said edible composition to a shaping process in order to obtain said food product, 9. The method according to claim 8, characterized in that the particle size of the particles is 100-300 mesh. 10. The method according to claim 8, wherein the forming further comprises: making the edible composition into the form of capsules, tablets, granules or granules. 11. Use of the edible composition according to any one of claims 1 to 5 in preparing a preparation for at least one of improving gastrointestinal function and enhancing human immunity.